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respectively.7,8
There is some evidence tha
prevalence of PCOS may be hig
populations with increased ris
insulin resistance and metaboli
ease (eg, PCOS was found in 1
Mexican–American women w1) · 16 January 2012Objective:  To document the prevalence of polycystic ovary syndrome (PCOS) 
and its associated characteristics in a sample of urban Indigenous women.
Design:  A cross-sectional survey of Indigenous women, including biochemical 
and anthropometric assessments. PCOS was assessed using the National 
Institutes of Health 1990 criteria.
Setting and participants:  Indigenous women, aged 15–44 years, living in a 
defined area in and around Darwin, Northern Territory, Australia, September 
2003 – March 2005.
Main outcome measures:  Proportion of participants with PCOS overall and 
measures of obesity.
Results:  Among 248 women eligible for assessment, the proportion who had 
PCOS was 15.3% (95% CI, 10.8%–19.8%). The proportion with PCOS was 
similar across age groups, but was significantly higher (P= 0.001) in women 
with a body mass index (BMI) of  30.0 kg/m2 (30.5%) compared with women 
with a BMI of 25.0–29.9 kg/m2 (8.2%) or a BMI of < 25.0 kg/m2 (7.0%).
Conclusions:  A high proportion of these Indigenous women had PCOS. The 
significant relationship with obesity gives a strong rationale for screening for 
PCOS during routine care of Indigenous women who are obese and of 
reproductive age.
Abstractol
(P
enP ycystic ovary syndromeCOS) is the most commondocrine problem in women
of reproductive age.1 The diagnosis is
generally based on three components:
(i) ovarian dysfunction, as manifested
by oligomenorrhoea or anovulation;
(ii) polycystic ovaries on ultrasound
examination; and (iii) evidence of
hyperandrogenism, either biochemi-
cal or clinical.2 The National Institutes
of Health (NIH) 1990 definition, one
of the most widely used, includes two
of these, namely hyperandrogenae-
mia and anovulatory menstrual cycles,
and exclusion of other aetiologies.3
The Rotterdam consensus (2003) rec-
ommends any two of the three com-
ponents listed above, as well as
exclusion of other aetiologies.2 These
criteria for diagnosis of PCOS are
listed in Box 1.
PCOS may cause difficulties in
reproductive health with irregular
menstrual cycles, anovulation and
infertility, and is associated with
hyperinsulinaemia and insulin resist-
ance, impaired glucose tolerance, dia-
betes, dyslipidaemia and cardio-
vascular disease (CVD).1
The prevalence of PCOS is gener-
ally reported as 4%–8% of women of
reproductive age, regardless of ethni-
city. This range is based largely on
three studies — in Spain, the United
States and Greece — all of which used
NIH criteria for diagnosing PCOS.4-6
Most women in these studies were of
European origin, although the Ameri-
can study also included African
Americans.5 Studies of retrospective
birth cohorts in Finland and Australia,
also using the NIH criteria, showed
prevalences of 10.3% and 8.7%,
t the
her in
ks of
c dis-
3% of
hose
parents had a history of CVD).9 Many
factors associated with PCOS are
more common among Australian
Indigenous women, including obesity,
hyperinsulinism, diabetes, dyslipidae-
mia and a history of low birth-
weight.10,11 One small study of 35
Australian Aboriginal women found a
PCOS prevalence of 18%,12 suggest-
ing that PCOS may be more common
in Australian Indigenous women than
in other populations. Our study
assessed the prevalence of PCOS, and
the characteristics of women with and
without PCOS, in a group of urban
Indigenous women in Darwin, North-
ern Territory, Australia.
Methods
Study population and design
Data for our study were collected from
September 2003 to March 2005 as part
of the Darwin Region Urban Indigen-
ous Diabetes (DRUID) study, which
has been described in detail else-
where.13 Briefly, eligible DRUID par-
ticipants were volunteers aged  15
years who identified as Aboriginal
and/or Torres Strait Islander, had lived
in a defined geographical region in the
Darwin area for  6 months, and were
not living in an institution. Those who
gave consent underwent a health
examination, including collection of
blood and urine samples and clinical
and anthropometric measurements,
and completed a questionnaire.
Our study was limited to female
DRUID study participants who were
aged 15–44 years, and who agreed to
complete a questionnaire on women’s
reproductive health and/or to have
additional analyses of their blood
samples for androgen levels.
Women’s reproductive health 
questionnaire
Information was collected on men-
strual cycle frequency and regularity,
fertility and infertility, menopause,
past and present contraceptive use,
and presence and treatment of hir-
sutism and acne. Oligomenorrhoea
was defined as self-reported cycles
> 35 days apart, regardless of whether
they were described as regular or
irregular.
Anthropometry and blood pressure
The method of obtaining anthropo-
metric measures (weight, height,
body mass index [BMI] and waist : hip
ratio [WHR]) has been described pre-
viously.13 BMI categories were defined
as healthy (< 25.0 kg/m2), overweight
( 25.0 kg/m2 and < 30.0 kg/m2) and
Research
men with 
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 other aetiologies*
 and/or hirsutism
arker of polycystic 
’s syndrome.obese ( 30.0 kg/m2). WHR categories
were healthy (< 0.8) and overweight/
obese ( 0.8). Blood pressure was
measured in the sitting position after
5 min at rest using an automated
Welch Allyn Spot Vital Signs monitor
(Welch Allyn Medical Products, Ska-
neateles Falls, NY, USA).
Assays
Venepuncture was performed after an
overnight fast. Sex hormone-binding
globulin (SHBG) and androgen levels
were analysed by the Reproductive
Medicine Laboratory (RML) in
Adelaide. SHBG was measured with
an immunoradiometric assay (IRMA)
(Orion Diagnostica [IRMA Cat. No.
68563], Espoo, Finland); testosterone
was measured with a radioimmu-
noassay (RIA) kit (DSL-4100, Diag-
nostic System Laboratories, Webster,
Tex, USA); and anti-Müllerian hor-
mone (AMH) levels were measured
using a commercially available AMH
enzyme immunoassay (Beckman
Coulter, Marseille, France). Free
androgen index (FAI) was calculated
as: total testosterone (nmol/L) / SHBG
(nmol/L) × 10; and free testosterone
was calculated using the Vermeulen
equation, assuming a serum albumin
concentration of 43 g/L.14
To exclude other causes of hyperan-
drogenaemia and oligomenorrhoea,
apart from PCOS, women with an FAI
of > 5.4 plus oligomenorrhoea had
further analysis of their samples for
levels of 17-hydroxyprogesterone (17-
OHP), dehydroepiandrosterone sul-
fate (DHEAS), thyroid-stimulating
hormone (TSH), and prolactin. The
FAI cut-off of 5.4, chosen at the study
inception, was the upper limit of nor-
mal for women tested at the RML.
The RML also performed these
analyses: 17-OHP estimation with an
RIA kit (DSL-6800) and DHEAS level
using the DHEAS RIA kit (DSL-2700)
(Diagnostic System Laboratories);
and TSH and prolactin levels using
the ADVIA Centaur automated
chemiluminescence immunoassay
system (Bayer HealthCare, Australia).
Inter- and intra-assay coefficients of
all tests were < 10%.
Exclusion criteria
Excluded from assessment of PCOS
(Box 2) were women who were preg-
nant or breastfeeding; those who did
not consent to complete a reproduc-
tive health questionnaire; those with-
out androgen level assessment; those
who reported being menopausal,
using hormone replacement therapy
or hormonal contraception, or who
had had a hysterectomy or oophorec-
tomy (they may have had difficulty
recalling menstrual cycle regularity);
and those with missing information
about cycle regularity.
Classification of PCOS and 
associated categories (Box 1)
a) PCOS-NIH
PCOS was defined using NIH 1990
criteria. Information was available on
the presence of (i) self-reported men-
strual dysfunction; (ii) hyperandro-
genaemia; and (iii) exclusion of other
disorders.3 Menstrual dysfunction was
considered present for women with
oligomenorrhoea. Hyperandrogenae-
mia was defined as a circulating free
testosterone level > 34.2 pmol/L (the
95th percentile for a group of women
known to be free of PCOS whose
samples were assessed on the same
machine with the same assay as our
study). Although hirsutism was self-
reported as excess hair on the chin,
lip, chest or abdomen, this was not
used as a diagnostic criterion because
it was not assessed objectively by a
trained rater.
Women were included in the
PCOS-NIH group if they had: (i) oli-
gomenorrhoea; (ii) a free testosterone
level of > 34.2 pmol/L; and (iii) normal
values for prolactin, 17-OHP and
TSH.
b) Abnormal prolactin, 17-OHP and 
TSH values
Women with oligomenorrhoea and
elevated free testosterone levels were
excluded from a diagnosis of PCOS if
they had abnormal values for prolactin
(> 900IU/L), 17-OHP (> 10mmol/L),
and TSH (< 0.4 or > 4.7 mIU/L).
c) Possible but not definitive PCOS
Women were included in the “possi-
ble but not definitive” group if they
were not in either group (a) or (b)
above and had: (i) self-reported hir-
sutism plus oligomenorrhoea (possi-
ble PCOS-NIH); (ii) the two NIH
components of PCOS (oligomenor-
rhoea and hyperandrogenaemia), but
were missing measurements of 17-
OHP, prolactin or TSH and, therefore,
were unable to have abnormalities of
these excluded; or (iii) possible PCOS
by modified Rotterdam criteria of two
components of hyperandrogenaemia
or hirsutism, oligomenorrhoea and a
high AMH level. Women in this latter
group with completed investigations
(TSH, prolactin and 17-OHP) have
PCOS by these criteria.
AMH level was used as a surro-
gate for antral follicle count, as
described by Pigny et al.15 An AMH
cut-off of 23.0 pmol/L was deemed
1 Polycystic ovary syndrome (PCOS) — criteria for diagnosis and for classification of wo
associated characteristics
AMH = anti-Müllerian hormone.
     National Institutes of Health (NIH) 
1990 criteria
1.  Oligo- or anovulation
2.  Clinical and/or biochemical evidence 
of hyperandrogenism 
and exclusion of other aetiologies*
Diagnostic criteria for PCOS
     Deﬁnitive PCOS
NIH criteria
1.  Oligo- or anovulation
2.  Biochemical evidence of hyperandrogenism
and exclusion of other aetiologies*
     Possible but not deﬁnitive PCOS
NIH criteria
1.  Oligo- or anovulation
2.  Hirsutism 
or
1.  Oligo- or anovulation
2.  Biochemical evidence of hyperandrogenism
       but insufficient serum samples to exclude
Criteria used in our study
Modiﬁed Rotterdam criteria
Two of
1.  Oligo- or anovulation
2.  Biochemical evidence of hyperandrogenism
3.  Increased AMH level (> 23 pmol/L) as a m
ovaries
± exclusion of other aetiologies*
* Other aetiologies: congenital adrenal hyperplasia, androgen-secreting tumours and Cushing
     Rotterdam 2003 consensus
Two of
1.  Oligo- or anovulation
2.  Clinical and/or biochemical evidence 
of hyperandrogenism
3.  Polycystic ovaries
and exclusion of other aetiologies*63MJA 196 (1) · 16 January 2012
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polycystic ovaries, based on a study of
women in Adelaide with and without
PCOS. This level was shown to have a
sensitivity of 75% and a specificity of
90% in diagnosing polycystic ovaries
confirmed by ultrasound examina-
tion.16 However, in our study, corre-
lating AMH levels with ultrasound
results was not feasible; these women
are included as having possible PCOS
by the Rotterdam criteria,2 but no fur-
ther analysis of this group is reported
here.
d) Non-hyperandrogenic
This group includes women with no
hyperandrogenaemia or self-reported
hirsutism and an AMH level of
< 23.0 pmol/L. They had either regular
cycles (< 35 days) or oligomenorrhoea.
e) Hyperandrogenaemia
These women had free testosterone
levels of > 34.2 pmol/L, regular cycles
of < 35 days, and an AMH level of
< 23.0 pmol/L.
f) Idiopathic hirsutism
These women had self-reported hir-
sutism, but normal androgen levels
(free testosterone level, < 34.2pmol/L),
regular cycles of < 35 days, and an
AMH level of < 23.0 pmol/L.
Statistical analysis
Statistical analyses were performed
using Intercooled Stata 8.0 (Stata-
Corp, College Station, Tex, USA). Fre-
quencies, means, medians and SDs
were calculated, and data are pre-
sented as median (interquartile range
[IQR]). Overall differences across the
groups were compared using a
Kruskal–Wallis test and post-hoc pair-
wise comparisons were made using a
Mann–Whitney rank-sum test. A
two-tailed 2 test was used to com-
pare categorical variables.
Ethics approval
Our study was approved by the
Human Research Ethics Committee
of the Northern Territory Department
of Health and Menzies School of
Health Research, including its Abori-
ginal Ethics Sub-Committee. Our
study received guidance from an
Indigenous steering committee of
local community leaders.
Results
The selection of study participants is
shown in Box 2. Of 461 women, 424
(92.0%) answered the questionnaire,
419 had androgen levels measured
(90.9%), and 393 (85.2%) completed
both the questionnaire and had
androgen levels measured. Based on
estimated resident population figures
at June 2004,17 our participants repre-
sent at least 13%–14% of the eligible
women in this age group living in a
defined region of Darwin.
Of these 393 women, 248 fulfilled
all protocol criteria and were eligible
for assessment of PCOS (Box 3). The
median age of this group was 31.0
years (IQR, 22.0–38.0 years), median
BMI was 27.0 kg/m2 (IQR, 22.5–
32.6 kg/m2) and median WHR was
0.85 (IQR, 0.80–0.91).
Thirty-eight of these women
(15.3%; 95% CI, 10.8%–19.8%) met
the diagnosis of PCOS by NIH crite-
ria. The proportion of women with
PCOS increased with increasing BMI
(P = 0.001) from 7.0% (7/100) of the
“healthy” group, to 8.2% (5/61) of the
“overweight” group and 30.5% (25/82)
of the “obese” group. By contrast,
there was no significant difference in
the proportion of women with PCOS
between the healthy and overweight
categories according to WHR (P =
0.61): healthy 13.4% (9/67) versus
overweight 16.0% (29/181).
The remaining women were cate-
gorised as shown in Box 3: hyperan-
drogenaemia, 34 (13.7%); idiopathic
hirsutism, 25 (10.1%); non-hyperan-
drogenic, 79 (31.9%); abnormal 17-
OHP/TSH values, 9 (3.6%); and pos-
sible but not definitive PCOS, 61
(24.6%). The majority of the latter
group (n = 53) had possible PCOS by
the modified Rotterdam criteria. Two
additional women with insufficient
serum for measurement of AMH level
(one with a free testosterone level of
> 34.2 pmol/L, regular cycles and hir-
sutism, and the other with hirsutism
only) could not be allocated to the
above groups.
The characteristics of women in
four of these groups (PCOS, hyperan-
drogenaemia, idiopathic hirsutism
and non-hyperandrogenic ) are
reported in Box 4. Median age was
similar across the non-hyperandro-
genic, hyperandrogenaemia and
PCOS groups, but those with idio-
pathic hirsutism were significantly
older. Women with PCOS had the
highest median BMI (33.4 kg/m2) and
the highest systolic and diastolic
blood pressures. Total testosterone
and free testosterone levels were
2 Selection of study participants for assessment of prevalence of polycystic ovary 
syndrome
DRUID = Darwin Region Urban Indigenous Diabetes study. ◆
467 women (15–44 years) 
had consented to DRUID study
6 were pregnant or 
breastfeeding
424 consented to reproductive 
health questionnaire
419 consented to biochemical 
androgen assessment
YES
100 women not suitable for menstrual 
cycle assessment (excluded)
NO
293 women suitable for menstrual 
cycle assessment
45 women with menstrual cycle 
information missing, “don’t know” 
or “not applicable”
248 women with androgen 
assessment and usable
information on menstrual cycle
393 consented to both questionnaire and androgen assessment
Taking current hormonal contraception or hormone replacement therapy, or 
reported hysterectomy or menopause
11 did not consent to women’s 
health study1) · 16 January 2012
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ogenaemia, and 
)
P value 
(Kruskal–Wallis)
0.08
0.001
) 0.05
5) 0.06
) 0.06
0.001
0.001
0.001
0.001
0.19
0.12
ed with
◆ 
yndrome (PCOS)
 * Two women omitted, 
◆
rmal TSH levels
-NIH
eﬁnitive PCOS
genaemia
irsutism
ndrogenichighest and SHBG levels lowest in
women with PCOS and in those with
hyperandrogenaemia.
The proportion of women with dia-
betes was not significantly different
across these four groups (P = 0.12);
eight women had known diabetes
before participating in the DRUID
study and three in each of the non-
hyperandrogenic group and the
PCOS group were newly diagnosed
with diabetes during our study. No
significant differences were observed
in fasting glucose levels between the
groups (P = 0.19).
Discussion
Using the NIH 1990 criteria for diag-
nosis, PCOS was present in around
one in six (15.3%) urban Indigenous
women volunteering for our study in
Darwin. This proportion increased
with increasing BMI, reaching 30.5%
in those with a BMI of > 30.0 kg/m2.
Conversely, there was no significant
difference in the proportion of women
with PCOS with increasing WHR.
Given that Indigenous Australians
(both men and women) when they
gain weight have a centralised
(abdominal) pattern of fat distribu-
tion, an elevated WHR is not as good
a discriminator of increasing over-
weight and obesity as BMI is.18
The prevalence of PCOS in our
study group is higher than reported in
studies in other countries also using
NIH criteria — Spain (6.5%),4 the US
(4.0%),5 Greece (6.8%),6 and northern
Finland (10.3%).7 Another Australian
study in a non-Indigenous population
found a proportion of 8.7%,8 and a
study of Mexican–Americans found
that 13% had PCOS.9 However, dif-
ferences in study populations and
definitions of PCOS make it difficult
to compare these studies. In our
study, the proportion of women with
PCOS would almost certainly have
been higher using a different defini-
tion, given that at least 14 women
(5.6%) who did not meet the NIH
definition had PCOS according to
the modified Rotterdam criteria
described.
Recruitment strategies have varied
among the prevalence studies, from
population-based to employment-
based to volunteers for screening. The
women in our study were commu-
nity-based volunteers, but the larger
DRUID study in which they also par-
ticipated focused on diabetes screen-
ing. Therefore, women at high risk of
diabetes, or who were obese, may
have been more likely to participate.
Of the total number of women aged
15–44 years in the DRUID study, 8.3%
had known or newly diagnosed dia-
betes. Age-specific figures (2.9%
among 15–24 years, 8.8% among 25–
34 years and 13.8% among 35–44
years) were only slightly higher than
those self-reported for known diabe-
tes or high blood sugar levels in the
National Aboriginal and Torres Strait
Islander health survey (2004–05),19
which does not support an excess of
high-risk women selecting for screen-
ing. Similarly, while 33.7% of women
in our study were obese (BMI
> 30.0 kg/m2), this is consistent with
national data, and the median BMI in
our study was similar to that for
women in other PCOS prevalence
studies.5,8
Although the PCOS prevalence we
found is higher than that in previous
reports, the constraints of our study
suggest this prevalence may even be
an underestimate. Previously reported
prevalence studies have used a
number of androgen measurements
to determine hyperandrogenaemia,
whereas the definition used for
hyperandrogenaemia in our study
4 Characteristics of women (median [interquartile range]) by classification — non-hyperandrogenic, idiopathic hirsutism, hyperandr
polycystic ovary syndrome – National Institutes of Health criteria (PCOS-NIH)
Characteristics
Non-hyperandrogenic 
(n = 79)
Idiopathic hirsutism 
(n = 25)
Hyperandrogenaemia and 
regular cycles (n = 34) PCOS-NIH (n = 38
Age (years) 33.0 (23.0–39.0) 37.0 (34.0–40.0)*† 32.0 (23.0–38.0)‡ 31.5 (21.0–36.0)
Body mass index (kg/m2) 23.7 (20.7–27.6)* 27.4 (23.0–33.4)* 28.1 (25.5–34.2)* 33.4 (27.7–39.7)
Waist : hip ratio 0.83 (0.79–0.90)*‡ 0.87 (0.81–0.95) 0.85 (0.82–0.90) 0.86 (0.82–0.96
Systolic BP (mmHg) 106.0 (100.0–114.0)* 106.5 (101.5–121.0)* 106.8 (101.5–113.0) 112.3 (105.0–118.
Diastolic BP (mmHg) 69.5 (65.0–74.0)* 72.0 (66.0–77.5) 71.0 (63.5–77.0) 73.8 (67.0–80.0
Total testosterone (nmol/L) 1.3 (1.1–1.6)*‡ 1.3 (1.2–1.5)* 2.4 (1.9–2.6)‡ 2.3 (1.9–3.0)
Sex hormone-binding globulin (nmol/L) 41.6 (30.2–63.0)* 40.8 (24.7–46.6)* 20.8 (17.4–27.4) 19.4 (13.7–25.4)
Free testosterone (pmol/L) 21.0 (13.8–27.3)*‡ 23.7 (15.0–30.9)* 50.2 (44.0–60.0)‡ 50.9 (41.0–78.5)
Anti-Müllerian hormone (pmol/L) 14.8 (9.9–26.1) 10.3 (7.9–17.2) 12.2 (8.6–18.7) 29.9 (11.1–44.9)
Fasting glucose (mmol/L) 4.9 (4.7–5.4) 5.3 (4.8–5.5) 5.1 (4.9–5.4) 5.1 (4.8–5.7)
Diabetes, no. (%) 4 (5.1%) 4 (16.0%) 1 (2.9%) 5 (13.2%)
BP = blood pressure. P values based on pair-wise comparisons using a Mann–Whitney rank-sum test. *P< 0.05 compared with PCOS group; †P< 0.05 compar
non-hyperandrogenic group; ‡P< 0.05 compared with idiopathic hirsutism group.
3 Classification of eligible participants for assessment of prevalence of polycystic ovary s
17-OHP = 17-hydroxyprogesterone. TSH = thyroid-stimulating hormone. NIH = National Institutes of Health.
as insufficient serum was available for measuring anti-Müllerian hormone levels. 
248* women 
eligible for 
assessment 
of PCOS
108 with possible PCOS
9 (3.6%) with high 17-OHP or abno
38 (15.3%) with PCOS
61 (24.6%) with possible but not d
138 without PCOS
34 (13.7%) with hyperandro
25 (10.1%) with idiopathic h
79 (31.9%) were non-hypera65MJA 196 (1) · 16 January 2012
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this may have led to an underestima-
tion of prevalence. Finally, excluding
women using hormonal contracep-
tion may have biased the estimation
either way, with the direction depend-
ing on the reason for use. If hormonal
contraception was used for cycle con-
trol then it would likely have underes-
timated the true prevalence of PCOS.
However, no information was availa-
ble on reasons for contraceptive use.
Hirsutism, including self-reported
hirsutism, has been included as diag-
nostic of hyperandrogenism in PCOS
in a number of major prevalence stud-
ies.4,5,7-9 We did not use it as a diag-
nostic factor for PCOS in our study;
however, 38% of women reported
hair growth on their lip, chin or chest.
Previous studies found up to 82% of
women presenting with hirsutism
have PCOS, even those with a low
Ferriman–Gallwey score;20 thus
excluding hirsutism probably under-
estimated PCOS prevalence. Com-
pared with studies of women of
European origin, a higher proportion
of women in our study reported hir-
sutism, However, hirsutism varies
with ethnicity, and these figures are
consistent with reports in other Aus-
tralian Indigenous women (39.5%).12
The high prevalence of PCOS
found in our sample may be related to
the high risk of diabetes and obesity
in Australian Indigenous women, as
well as antenatal factors (low birth-
weight and diabetes in pregnancy) or
environmental factors (eg, diet, physi-
cal activity and smoking) that have an
impact on insulin sensitivity and hor-
mones such as testosterone and
SHBG. Community and health care
providers need to be aware of both
diagnosis and best-practice manage-
ment of PCOS21 so that there is a low
threshold for screening Indigenous
women for PCOS.
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